Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20639902 | 0.83 | NOTUM (0.70) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL20046238 | 0.81 | MAOA (0.68) | NOTUMJAK2ROCK2GSK3BMIF | |
| SCHEMBL17978524 | 0.79 | PTGS2 (0.51) | NOTUMJAK2ROCK2GSK3BMIF | |
| SCHEMBL15060974 | 0.79 | MIF (0.71) | NOTUMJAK2ROCK2GSK3BMIF | |
| SCHEMBL15892523 | 0.77 | NOTUM (0.49) | NOTUMJAK2ROCK2GSK3BMIF | |
| SCHEMBL13527245 | 0.77 | MIF (0.69) | NOTUMJAK2ROCK2GSK3BMIF | |
| SCHEMBL22873389 | 0.76 | MAOA (0.64) | NOTUMJAK2ROCK2GSK3BMIF | |
| SCHEMBL21156928 | 0.76 | MIF (0.52) | NOTUMJAK2ROCK2GSK3BMIF | |
| SCHEMBL13527022 | 0.76 | MIF (0.52) | NOTUMJAK2ROCK2GSK3BMIF | |
| SCHEMBL17978627 | 0.75 | MIF (0.51) | NOTUMJAK2ROCK2GSK3BMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | ABIVAX (FR) | 2020-01-21 | — | — | US | disclosed |
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | ABIVAX (FR) | 2018-05-10 | — | — | US | disclosed |
| US-9890112-B2 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | ABIVAX (FR) | 2018-02-13 | — | — | US | disclosed |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIETE SPLICOS (FR) | 2014-07-24 | — | — | US | disclosed |
| EP-2694061-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | Société Splicos (FR) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012131656-A2 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | SOCIÉTÉ SPLICOS (FR) | 2012-10-04 | — | — | WO | disclosed |
| EP-2505198-A1 | Compounds for use as therapeutic agents affecting p53 expression and/or activity | Société Splicos (FR) | 2012-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127353-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, TP53BP1, BCOR | NOTUM 3893/4885JAK2 1752/4885ROCK2 3050/4885 |
| US-10538485-B2 | Compounds for use as therapeutic agents affecting P53 expression and/or activity | TP53, TP53BP1, BCOR | NOTUM 3893/4885JAK2 1752/4885ROCK2 3050/4885 |
| US-20140206690-A1 | COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY | TP53, CBR3, TP53BP1 | NOTUM 4282/4885JAK2 2100/4885ROCK2 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.